Biosimilar Maker Leverages IPR to Avoid Patent Dance and Obtain Early Market Entry
Bio Law Blog
JUNE 21, 2020
Amgen Inc. and Alexion Pharmaceuticals Inc. settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. Alexion is the maker of Soliris (eculizumab), a humanized monoclonal antibody against complement protein C5, indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)
Let's personalize your content